PARP1 and neoplasm: The key mechanism for acquired resistance to PARP inhibitor is the restoration of efficient homologous recombination (HR) DNA repair in tumor cells through secondary genetic alterations (e.g., secondary mutations in BRCA1/2 or other critical genes on the pathway of HR) [15, 16].